Alphamab Oncology (9966.HK)

HKD 7.85

(21.52%)

Total Liabilities Summary of Alphamab Oncology

  • Alphamab Oncology's latest annual total liabilities in 2023 was 465 Million CNY , down -16.94% from previous year.
  • Alphamab Oncology's latest quarterly total liabilities in 2024 Q2 was 513.25 Million CNY , down 0.0% from previous quarter.
  • Alphamab Oncology reported annual total liabilities of 559.85 Million CNY in 2022, down -32.94% from previous year.
  • Alphamab Oncology reported annual total liabilities of 834.8 Million CNY in 2021, up 127.82% from previous year.
  • Alphamab Oncology reported quarterly total liabilities of 465 Million CNY for 2023 Q4, down 0.0% from previous quarter.
  • Alphamab Oncology reported quarterly total liabilities of 465 Million CNY for 2023 FY, down -16.94% from previous quarter.

Annual Total Liabilities Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Total Liabilities of Alphamab Oncology (2023 - 2017)

Year Total Liabilities Total Liabilities Growth
2023 465 Million CNY -16.94%
2022 559.85 Million CNY -32.94%
2021 834.8 Million CNY 127.82%
2020 366.43 Million CNY -14.52%
2019 428.65 Million CNY -60.81%
2018 1.09 Billion CNY 5297.81%
2017 20.26 Million CNY 0.0%

Peer Total Liabilities Comparison of Alphamab Oncology

Name Total Liabilities Total Liabilities Difference
Uni-Bio Science Group Limited 152.81 Million HKD -204.284%
CK Life Sciences Int'l., (Holdings) Inc. 7.05 Billion HKD 93.412%